Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) (MarketWatch)
Biohaven Pharmaceutical Holding Co. Ltd. BHVN, -12.72% shares dropped nearly 23% in premarket trade Monday after the company released data from two phase 3 clinical trials for its migraine drug rimegepant. The company touted that the drug had met both registrational co-primary endpoints in the two trials, and said it plans to file for approval with the Food and Drug Administration in 2019, but it will also have a formidable rival in this drug category, biopharmaceutical company Allergan AGN, -0.90% Allergan shares rose 1.6% in premarket trade.
Facebook, Inc. (NASDAQ:FB) (Reuters)
WASHINGTON (Reuters) – Facebook Inc (FB.O) shares fell as much as 6.5 percent on Monday after the main U.S. consumer protection regulator said it was investigating how the social network allowed data of 50 million users to get into the hands of a political consultancy. Scrutiny by the U.S. Federal Trade Commission, which generally confirms the existence of an investigation only in cases of significant public interest, adds to pressure from lawmakers in the United States and Europe for Facebook Chief Executive Mark Zuckerberg to explain how his company handles user data. Facebook shares briefly dipped below $150 on Monday for the first time since July 2017, before recouping some losses. They were down 3.1 percent at $154.37 in afternoon trading.
Longfin Corp (NASDAQ:LFIN) (CNBC)
Shares of Longfin, which have spiked astronomically on ties to blockchain technology, fell Monday after a tweet from noted short-selling firm Citron Research. Longfin (Ticker: LFIN) shares briefly tumbled 13.5 percent and were trading 8.9 percent lower near $64.77 as of 11:13 a.m. ET. The tiny, little-known stock surged more than 1,200 percent over two trading days in mid-December after the financial technology company said it is purchasing a firm focused on blockchain, the technology behind cryptocurrencies such as bitcoin.
Verona Pharma PLC – ADR (NASDAQ:VRNA) (Benzinga)
Verona Pharma plc shares jumped 44.4 percent to $23.3999 after the company disclosed positive top-line data from Phase 2b clinical trial of RPL554 for the maintenance treatment of chronic obstructive pulmonary disease.